Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia is promoting Brenzys

Executive Summary

Merck, Sharp & Dohme’s Brenzys (etanercept) has become the first biosimilar to benefit from specific uptake drivers through Australia’s Pharmaceutical Benefits Scheme (PBS). Under the terms of a 2017-2018 budget agreement with industry and pharmacists, doctors are now encouraged to prescribe the Brenzys biosimilar rather than Pfizer’s Enbrel reference brand for treatment-naïve patients, while Australia’s Department of Health has streamlined the priorauthorisation process for Brenzys but not for Enbrel.

Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

GB000055

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel